You are here

diabetes

With filing in Sanofi and Mylan insulin lawsuit, FTC amps up scrutiny on pharma's patent tactics

With filing in Sanofi and Mylan insulin lawsuit, FTC amps up scrutiny on pharma's patent tactics

Fierce Pharma

Flag link:

Beyond insulin: Medical expands patient access to diabetes supplies

Beyond insulin: Medical expands patient access to diabetes supplies

Medical Marketing and Media

Flag link:

Novo Nordisk sets aside $6bn to boost production capacity

Novo Nordisk sets aside $6bn to boost production capacity

Pharmaphorum

drug manufacturing

Flag link:

Novo Nordisk to discontinue Levemir insulin in U.S. market

Novo Nordisk to discontinue Levemir insulin in U.S. market

Reuters

Flag link:

An obesity drug biotech gets buy-in from Eli Lilly, venture firms

An obesity drug biotech gets buy-in from Eli Lilly, venture firms

BioPharma Dive

Flag link:

Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.

Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.

Motley Fool

Flag link:

Belgium plans temporary ban on use of Ozempic for weight loss

Belgium plans temporary ban on use of Ozempic for weight loss

Yahoo/Reuters

Flag link:

Insulet Omnipod 5 iPhone App FDA Cleared

Insulet Omnipod 5 iPhone App FDA Cleared

Medical Devices and Diagnostics Industry

insulin delivery

Flag link:

Fresenius Medical: effect of drugs like Ozempic on patient numbers is neutral

Fresenius Medical: effect of drugs like Ozempic on patient numbers is neutral

Yahoo/Reuters

Fresenius Medical Care

Flag link:

Novo Ends Semaglutide Kidney Study Early Due to Strong Efficacy Signals

Novo Ends Semaglutide Kidney Study Early Due to Strong Efficacy Signals

BioSpace

clinical trials

chronic kidney disease

Flag link:

Abbott’s Biowearable Performs Well In U.K. Ahead Of U.S. Launch

Abbott’s Biowearable Performs Well In U.K. Ahead Of U.S. Launch

Forbes

Flag link:

2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not

2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not

Motley Fool

Flag link:

At Viatris' request, US agency will review another Novo Nordisk patent on semaglutide

At Viatris' request, US agency will review another Novo Nordisk patent on semaglutide

Fierce Pharma

Flag link:

Lilly names new diabetes and obesity chief as Mounjaro sales take off

Lilly names new diabetes and obesity chief as Mounjaro sales take off

BioPharma Dive

Flag link:

FDA Adds New Warning for Ileus to Ozempic Label

FDA Adds New Warning for Ileus to Ozempic Label

HCP Live

Flag link:

Why a hidden message in Ozempic’s logo represents a big shift in drug branding

Why a hidden message in Ozempic’s logo represents a big shift in drug branding

Fast Company

Flag link:

FDA panel votes against diabetes implant due to safety concerns

FDA panel votes against diabetes implant due to safety concerns

Reuters

Flag link:

Intarcia, a failed diabetes "unicorn," could be resurrected

Intarcia, a failed diabetes "unicorn," could be resurrected

Axios

Flag link:

Eli Lilly sues clinics allegedly selling knockoff versions of Mounjaro diabetes drug

Eli Lilly sues clinics allegedly selling knockoff versions of Mounjaro diabetes drug

CNBC

Flag link:

Novo Nordisk taps Aspen to help produce insulin for Africa

Novo Nordisk taps Aspen to help produce insulin for Africa

Fierce Pharma

Aspen Pharmacare

drug manufacturing

Flag link:

Pages